EU Approvals: J&J's Darzalex Steps Ahead With New Indication
Keytruda Cleared For First-Line Head & Neck Cancer
Executive Summary
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.